Community post

Eligo Bioscience just announced the issuance by the US Patent and Trademark Office of the first patent in a wide family covering genetic engineering of Cutibacterium acnes to support therapeutic interventions in multiple serious skin disorders. This pioneering work also provides unique opportunities to leverage the skin’s immune system for oncological, vaccination or desensitization applications.